Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Autoimmune drugs market size to increase by USD 29,314.5 million: North America will account for 51% of market growth - Technavio

Global Autoimmune Drugs Market 2023-2027

News provided by

Technavio

Feb 10, 2023, 05:30 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, Feb. 10, 2023 /PRNewswire/ -- The Autoimmune Drugs Market by Therapy Area, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 6.39% and register an incremental growth of USD 29,314.5 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. The report includes historic market data from 2017 to 2021. In 2017, the information services market was valued at USD 69,136.12 million. Download a PDF sample report

Continue Reading
Technavio has announced its latest market research report titled Global Autoimmune Drugs Market 2023-2027
Technavio has announced its latest market research report titled Global Autoimmune Drugs Market 2023-2027

Company profiles

The autoimmune drugs market report includes information on the key products and recent developments of leading vendors, including:

  • AbbVie Inc.: The company offers autoimmune drugs to treat autoimmune disease and cancer with medicine such as CUG252, a potential best-in-class Treg selective IL2 mutein.
  • Amgen Inc.: The company offers autoimmune drugs such as TAVNEOS, adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody.
  • AstraZeneca Plc: The company offers autoimmune drugs to improve patient outcomes and reframe patient care in other eosinophil-driven diseases that cause debilitating symptoms for patients and dramatically decrease their quality of life.
  • Bristol Myers Squibb Co.: The company offers autoimmune drugs that are used to treat moderate to severe plaque psoriasis.
  • Cardinal Health Inc.
  • Delphis Pharmaceutical India
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • To gain access to more vendor profiles available with Technavio, buy the report!

Regional analysis

Based on region, the global autoimmune drugs market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America is estimated to account for 51% of the growth of the global market during the forecast period. Factors such as increasing incidence rates of autoimmune diseases and the prevalence of rheumatoid arthritis among the rising aging population in the US are attributed to the increasing market size of North America.

Market dynamics

The market is driven by factors such as a strong R&D pipeline, targeted therapeutic mechanisms of biologics, and the introduction of affordable biosimilars. However, the high cost of biologics is hindering the market growth.

Competitive analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a sample

Market segmentation

  • Based on the therapy area, the market is segmented into rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and others. The advanced burn care segment accounted for the largest share of the market in 2022.
  • Based on the distribution channel, the market is segmented into hospitals, pharmacies, drug stores/retail pharmacies, and online.
  • Based on geography, the market is segmented into North America, Europe, Asia, and Rest Of World (ROW). North America held the largest share of the market in 2022.

Related Reports:

The autoimmune hemolytic anemia therapeutics market is estimated to grow at a CAGR of 9.1% between 2022 and 2027. The size of the market is forecasted to increase by USD 268.22 million. This report extensively covers market segmentation by product (Corticosteroids, monoclonal antibodies, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

The darier disease drugs market size is expected to increase by USD 45.37 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.6%. This report extensively covers market segmentation by product (topical retinoids, oral retinoids, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this Autoimmune drugs market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the autoimmune drugs market between 2023 and 2027
  • Precise estimation of the autoimmune drugs market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of Autoimmune drugs market vendors

Autoimmune drugs market Scope

Report Coverage

Details

Page number

173

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.39%

Market growth 2023-2027

USD 29,314.5 million

Market structure

Fragmented

YoY growth 2022-2023(%)

5.87

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 51%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., AdvaCare Pharma, Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cardinal Health Inc., Delphis Pharmaceutical India, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Medexus Pharmaceuticals Inc., Parvus Therapeutics Inc., Prometheus Laboratories Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Wellona Pharma

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio's heath care market reports

Table of contents:

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Area
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027 
    • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global autoimmune drugs market 2017 - 2021
    • Exhibit 18: Historic Market Size – Data Table on Global autoimmune drugs market 2017 - 2021 ($ million)
  • 4.2 Therapy area Segment Analysis 2017 - 2021
    • Exhibit 19: Historic Market Size – Therapy area Segment 2017 - 2021 ($ million)
  • 4.3 Distribution channel Segment Analysis 2017 - 2021
    • Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021 
    • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021 
    • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary 
    • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers 
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers 
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants 
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes 
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry 
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition 
    • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy Area

  • 6.1 Market segments 
    • Exhibit 30: Chart on Therapy Area - Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Therapy Area - Market share 2022-2027 (%)
  • 6.2 Comparison by Therapy Area 
    • Exhibit 32: Chart on Comparison by Therapy Area
    • Exhibit 33: Data Table on Comparison by Therapy Area
  • 6.3 Rheumatoid arthritis - Market size and forecast 2022-2027
    • Exhibit 34: Chart on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 35: Data Table on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 36: Chart on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
  • 6.4 Multiple sclerosis - Market size and forecast 2022-2027
    • Exhibit 38: Chart on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 39: Data Table on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 40: Chart on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
  • 6.5 Psoriasis - Market size and forecast 2022-2027
    • Exhibit 42: Chart on Psoriasis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 43: Data Table on Psoriasis - Market size and forecast 2022-2027 ($ million)
    • Exhibit 44: Chart on Psoriasis - Year-over-year growth 2022-2027 (%)
    • Exhibit 45: Data Table on Psoriasis - Year-over-year growth 2022-2027 (%)
  • 6.6 Inflammatory bowel disease - Market size and forecast 2022-2027 
    • Exhibit 46: Chart on Inflammatory bowel disease - Market size and forecast 2022-2027 ($ million)
    • Exhibit 47: Data Table on Inflammatory bowel disease - Market size and forecast 2022-2027 ($ million)
    • Exhibit 48: Chart on Inflammatory bowel disease - Year-over-year growth 2022-2027 (%)
    • Exhibit 49: Data Table on Inflammatory bowel disease - Year-over-year growth 2022-2027 (%)
  • 6.7 Others - Market size and forecast 2022-2027
    • Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
    • Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
    • Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
    • Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 6.8 Market opportunity by Therapy Area 
    • Exhibit 54: Market opportunity by Therapy Area ($ million)

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments 
    • Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
    • Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • 7.2 Comparison by Distribution Channel 
    • Exhibit 57: Chart on Comparison by Distribution Channel
    • Exhibit 58: Data Table on Comparison by Distribution Channel
  • 7.3 Hospital - Market size and forecast 2022-2027
    • Exhibit 59: Chart on Hospital - Market size and forecast 2022-2027 ($ million)
    • Exhibit 60: Data Table on Hospital - Market size and forecast 2022-2027 ($ million)
    • Exhibit 61: Chart on Hospital - Year-over-year growth 2022-2027 (%)
    • Exhibit 62: Data Table on Hospital - Year-over-year growth 2022-2027 (%)
  • 7.4 Pharmacy - Market size and forecast 2022-2027
    • Exhibit 63: Chart on Pharmacy - Market size and forecast 2022-2027 ($ million)
    • Exhibit 64: Data Table on Pharmacy - Market size and forecast 2022-2027 ($ million)
    • Exhibit 65: Chart on Pharmacy - Year-over-year growth 2022-2027 (%)
    • Exhibit 66: Data Table on Pharmacy - Year-over-year growth 2022-2027 (%)
  • 7.5 Drug store/Retail pharmacy - Market size and forecast 2022-2027 
    • Exhibit 67: Chart on Drug store/Retail pharmacy - Market size and forecast 2022-2027 ($ million)
    • Exhibit 68: Data Table on Drug store/Retail pharmacy - Market size and forecast 2022-2027 ($ million)
    • Exhibit 69: Chart on Drug store/Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • Exhibit 70: Data Table on Drug store/Retail pharmacy - Year-over-year growth 2022-2027 (%)
  • 7.6 Online - Market size and forecast 2022-2027
    • Exhibit 71: Chart on Online - Market size and forecast 2022-2027 ($ million)
    • Exhibit 72: Data Table on Online - Market size and forecast 2022-2027 ($ million)
    • Exhibit 73: Chart on Online - Year-over-year growth 2022-2027 (%)
    • Exhibit 74: Data Table on Online - Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Distribution Channel
    • Exhibit 75: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview 
    • Exhibit 76: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation 
    • Exhibit 77: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 78: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison 
    • Exhibit 79: Chart on Geographic comparison
    • Exhibit 80: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
    • Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
    • Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
    • Exhibit 85: Chart on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 86: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 87: Chart on Europe - Year-over-year growth 2022-2027 (%)
    • Exhibit 88: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
    • Exhibit 89: Chart on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 90: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 91: Chart on Asia - Year-over-year growth 2022-2027 (%)
    • Exhibit 92: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
    • Exhibit 93: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 94: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 95: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • Exhibit 96: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
    • Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
    • Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027
    • Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%)
    • Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 Canada - Market size and forecast 2022-2027
    • Exhibit 105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
    • Exhibit 106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
    • Exhibit 107: Chart on Canada - Year-over-year growth 2022-2027 (%)
    • Exhibit 108: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.10 China - Market size and forecast 2022-2027
    • Exhibit 109: Chart on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 110: Data Table on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 111: Chart on China - Year-over-year growth 2022-2027 (%)
    • Exhibit 112: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.11 UK - Market size and forecast 2022-2027
    • Exhibit 113: Chart on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 114: Data Table on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 115: Chart on UK - Year-over-year growth 2022-2027 (%)
    • Exhibit 116: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography 
    • Exhibit 117: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges 
    • Exhibit 118: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape 
    • Exhibit 119: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption 
    • Exhibit 120: Overview on factors of disruption
  • 11.4 Industry risks 
    • Exhibit 121: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered 
    • Exhibit 122: Vendors covered
  • 12.2 Market positioning of vendors 
    • Exhibit 123: Matrix on vendor position and classification
  • 12.3 AbbVie Inc. 
    • Exhibit 124: AbbVie Inc. - Overview
    • Exhibit 125: AbbVie Inc. - Product / Service
    • Exhibit 126: AbbVie Inc. - Key news
    • Exhibit 127: AbbVie Inc. - Key offerings
  • 12.4 Amgen Inc. 
    • Exhibit 128: Amgen Inc. - Overview
    • Exhibit 129: Amgen Inc. - Product / Service
    • Exhibit 130: Amgen Inc. - Key offerings
  • 12.5 AstraZeneca Plc 
    • Exhibit 131: AstraZeneca Plc - Overview
    • Exhibit 132: AstraZeneca Plc - Product / Service
    • Exhibit 133: AstraZeneca Plc - Key news
    • Exhibit 134: AstraZeneca Plc - Key offerings
  • 12.6 Bristol Myers Squibb Co. 
    • Exhibit 135: Bristol Myers Squibb Co. - Overview
    • Exhibit 136: Bristol Myers Squibb Co. - Product / Service
    • Exhibit 137: Bristol Myers Squibb Co. - Key news
    • Exhibit 138: Bristol Myers Squibb Co. - Key offerings
  • 12.7 Cardinal Health Inc. 
    • Exhibit 139: Cardinal Health Inc. - Overview
    • Exhibit 140: Cardinal Health Inc. - Business segments
    • Exhibit 141: Cardinal Health Inc. - Key news
    • Exhibit 142: Cardinal Health Inc. - Key offerings
    • Exhibit 143: Cardinal Health Inc. - Segment focus
  • 12.8 Delphis Pharmaceutical India 
    • Exhibit 144: Delphis Pharmaceutical India - Overview
    • Exhibit 145: Delphis Pharmaceutical India - Product / Service
    • Exhibit 146: Delphis Pharmaceutical India - Key offerings
  • 12.9 Eli Lilly and Co. 
    • Exhibit 147: Eli Lilly and Co. - Overview
    • Exhibit 148: Eli Lilly and Co. - Product / Service
    • Exhibit 149: Eli Lilly and Co. - Key offerings
  • 12.10 F. Hoffmann La Roche Ltd. 
    • Exhibit 150: F. Hoffmann La Roche Ltd. - Overview
    • Exhibit 151: F. Hoffmann La Roche Ltd. - Business segments
    • Exhibit 152: F. Hoffmann La Roche Ltd. - Key news
    • Exhibit 153: F. Hoffmann La Roche Ltd. - Key offerings
    • Exhibit 154: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.11 GlaxoSmithKline Plc 
    • Exhibit 155: GlaxoSmithKline Plc - Overview
    • Exhibit 156: GlaxoSmithKline Plc - Business segments
    • Exhibit 157: GlaxoSmithKline Plc - Key offerings
    • Exhibit 158: GlaxoSmithKline Plc - Segment focus
  • 12.12 Hikma Pharmaceuticals Plc 
    • Exhibit 159: Hikma Pharmaceuticals Plc - Overview
    • Exhibit 160: Hikma Pharmaceuticals Plc - Business segments
    • Exhibit 161: Hikma Pharmaceuticals Plc - Key offerings
    • Exhibit 162: Hikma Pharmaceuticals Plc - Segment focus
  • 12.13 Johnson and Johnson 
    • Exhibit 163: Johnson and Johnson - Overview
    • Exhibit 164: Johnson and Johnson - Business segments
    • Exhibit 165: Johnson and Johnson - Key news
    • Exhibit 166: Johnson and Johnson - Key offerings
    • Exhibit 167: Johnson and Johnson - Segment focus
  • 12.14 Parvus Therapeutics Inc. 
    • Exhibit 168: Parvus Therapeutics Inc. - Overview
    • Exhibit 169: Parvus Therapeutics Inc. - Product / Service
    • Exhibit 170: Parvus Therapeutics Inc. - Key offerings
  • 12.15 Sanofi SA 
    • Exhibit 171: Sanofi SA - Overview
    • Exhibit 172: Sanofi SA - Business segments
    • Exhibit 173: Sanofi SA - Key news
    • Exhibit 174: Sanofi SA - Key offerings
    • Exhibit 175: Sanofi SA - Segment focus
  • 12.16 Takeda Pharmaceutical Co. Ltd. 
    • Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Overview
    • Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Product / Service
    • Exhibit 178: Takeda Pharmaceutical Co. Ltd. - Key news
    • Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 12.17 Teva Pharmaceutical Industries Ltd. 
    • Exhibit 180: Teva Pharmaceutical Industries Ltd. - Overview
    • Exhibit 181: Teva Pharmaceutical Industries Ltd. - Business segments
    • Exhibit 182: Teva Pharmaceutical Industries Ltd. - Key news
    • Exhibit 183: Teva Pharmaceutical Industries Ltd. - Key offerings
    • Exhibit 184: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist 
    • Exhibit 185: Inclusions checklist
    • Exhibit 186: Exclusions checklist
  • 13.3 Currency conversion rates for US$ 
    • Exhibit 187: Currency conversion rates for US$
  • 13.4 Research methodology 
    • Exhibit 188: Research methodology
    • Exhibit 189: Validation techniques employed for market sizing
    • Exhibit 190: Information sources
  • 13.5 List of abbreviations 
    • Exhibit 191: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.